InvestSMART

Oncosil Medical Limited (ASX:OSL)

ALERT: Price-sensitive ASX Announcement for OSL
Current share price for OSL : $1.075 -0.035 (-3.15%)+
Announcement
Release
30 Jul 2026 8:42AM
Price at Release
$1.110
Full Release
download
Summary
OncoSil Medical Limited reported significant advancements in its quarterly activities and cash flow report for the period ending 30 June 2026. Key achievements included increased sales growth driven by the broader adoption of its OncoSil™ device across Europe, major regulatory milestones such as the advancement of the FDA's Humanitarian Device Exemption application for distal cholangiocarcinoma to the final review stage, and obtaining TGA approval in Australia for unresectable locally advanced pancreatic cancer (LAPC). The company closed the quarter with $6.5 million in cash, showing disciplined financial management while navigating market expansions and regulatory processes. Research and development outflows are expected to stabilize as key trials conclude. Strategic priorities include expanding market access and completing a new manufacturing facility. The quarterly financials reflect a net cash outflow from operating activities of $2.6 million, with significant receipts from customers and continued investment in market growth.
Key Points
  • Strong sales growth in Europe.
  • FDA HDE application advanced to final review.
  • TGA approval in Australia achieved.
  • Cash position at $6.5 million end of June 2026.
  • R&D cash outflows stabilizing.
  • Focus on strategic market expansion.
  • Completion of new manufacturing facility.
  • Net cash outflow from operations $2.6 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.